Gender Difference of Serum Micro RNA-155 in Multiple Sclerosis Patients | ||||
| Journal of Current Medical Research and Practice | ||||
| Article 14, Volume 9, Issue 4, October 2024, Page 129-136 PDF (232.3 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jcmrp.2024.276604.1031 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Sally M. Bakkar1; Lamia A. I. Zayan  1; Sahar E.M. El-Deek1; Ahmed Nasreldein2
| ||||
| 1Department of Biochemistry and Molecular Biology Faculty of Medicine, Assiut University, Assiut, Egypt. | ||||
| 2Department of Neurology and Psychiatry Faculty of Medicine, Assiut University, Assiut, Egypt. | ||||
| Abstract | ||||
| Background and Objectives MS is becoming more commonplace globally, and its socioeconomic impact on society is becoming more significant. MS affects females nearly three times more frequently than males; male and female hormonal and genetic variations majorly influence health and disease. MicroRNAs, in particular, are of great interest because they can have a wide-ranging impact on downstream signaling pathways; variations in miRNA expression between men and women can make the biological and physiological disparities between the sexes easier to understand. Methods The level of miR-155 in the serum of 30 multiple sclerosis patients (21 females and 9 males) was assessed by real-time PCR. Results Serum expression of miR-155 was significantly higher in male MS patients than in females; no significant difference was detected between patients on disease-modifying therapy (DMT) and naïve ones. Conclusion MiR-155 sex-dependent differences suggest potential gender-specific roles in neuroinflammation. | ||||
| Keywords | ||||
| MiR-155; Multiple Sclerosis (MS); Gender/Sex Difference; DMT | ||||
|
Statistics Article View: 105 PDF Download: 80 |
||||
